文献速递抗菌药物管理

分子快速诊断检测在血流感染中的实施与优化

Implementation and optimization of molecular rapid diagnostic tests for bloodstream infections.
PubMed 文献 · Am J Health Syst Pharm · 2018-07-03

本文综述了分子快速诊断检测(mRDTs)作为抗菌药物管理干预措施在血流感染(BSIs)患者中的实施与优化。mRDTs在抗菌药物优化和患者结局方面已显示出一致且有意义的结果。药师在机构内实施抗菌药物管理计划时应将mRDTs视为血流感染患者的标准诊疗。

要点

  • mRDTs是强有力的抗菌药物管理干预措施之一。
  • 优化mRDTs需要充分的诊断管理,评估成本降低与监管要求。
  • 选择mRDT需熟悉仪器性能与机构抗菌谱。

核心结论

  • mRDTs已证明能够成为最强大的抗菌药物管理干预措施之一。
  • 药师在机构内实施抗菌药物管理计划时应考虑将mRDTs作为血流感染患者的标准诊疗。

研究设计与样本

  • 综述,回顾了mRDTs作为抗菌药物管理干预措施在血流感染患者中的实施与优化。

主要发现

  • mRDTs在抗菌药物优化和患者结局方面已显示出一致且有意义的结果。
  • 即使在感染病和抗菌药物管理培训的药师中,对可用mRDTs及其最佳实施与优化也存在显著的知识和熟悉度差距。
  • 鉴于感染病和/或抗菌药物管理培训药师缺乏,建立抗菌药物管理计划的要求将需要非感染病/抗菌药物管理培训的药师在其机构内实施管理干预,可能包括mRDTs。

关键数值与推荐

  • 所有经联合委员会认证的美国急性护理医院均要求实施抗菌药物管理计划(ASP)。

临床怎么用

  • 优化mRDTs需要充分的诊断管理,具体评估mRDT实施如何降低成本和协助满足抗菌药物管理监管要求。
  • 了解这些技术如何增强现有微生物学和抗菌药物管理工作流程至关重要。
  • 选择正确的mRDT需要熟悉仪器性能和机构抗菌谱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The implementation and optimization of molecular rapid diagnostic tests (mRDTs) as an antimicrobial stewardship intervention for patients with bloodstream infections (BSIs) are reviewed. SUMMARY: All U.S. acute care hospitals accredited by the Joint Commission are required to implement an antimicrobial stewardship program (ASP). Of the many interventions available to ASPs, mRDTs have demonstrated consistent, meaningful results on antimicrobial optimization and patient outcomes. Even among infectious diseases and antimicrobial stewardship-trained pharmacists, significant knowledge and familiarity gaps exist regarding available mRDTs and how best to implement and optimize them. Given the paucity of infectious diseases and/or antimicrobial stewardship-trained pharmacists, the mandates for establishing ASPs will require non-infectious diseases/antimicrobial stewardship-trained pharmacists to implement stewardship interventions, which may include mRDTs, within their institution. Optimization of mRDTs requires adequate diagnostic stewardship, specifically evaluating how mRDT implementation may decrease costs and assist in meeting antimicrobial stewardship regulatory requirements. Knowledge of how these technologies will augment existing microbiology and antimicrobial stewardship workflow is essential. Finally, selecting the right mRDT necessitates familiarity with the instrument's capabilities and with the institutional antibiogram. CONCLUSION: mRDTs have demonstrated the ability to be one of the most powerful antimicrobial stewardship interventions. Pharmacists required to implement an ASP in their institution should consider mRDTs as standard of care for patients with BSIs.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Wenzler E, Timbrook TT, Wong JR, et al. Implementation and optimization of molecular rapid diagnostic tests for bloodstream infections. Am J Health Syst Pharm. 2018. PMID: 29970407. doi:10.2146/ajhp170604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。